PEGylated Protein Therapeutics Market Anticipated to Grow at an Impressive Rate during the Period

The PEGylated Protein Therapeutics Market is estimated at $ 1,038 million in 2017 and is projected to grow at an average annual rate of 6.9% from 2018 to 2025, reaching $ 17.813 billion by 2025. North America is expected to have the highest revenue contribution over the forecast period.

PEGylation is the process of adding active polyethylene glycol (PEG) to various forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. Chemical modification due to PEGylation brings about various advantages such as extended half-life of the drug with lower toxicity and increased proteolytic protection than the untreated protein therapeutic. PEGylated protein therapeutics are used in cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and many other conditions.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/3726

The report provides an extensive competitive analysis and profiles of the key market players such as

·         Amgen Inc.

·         AstraZeneca PLC

·         Biogen Inc.

·         F. Hoffmann-La Roche Ltd. (Genentech Inc.)

·         Horizon Pharma plc.

·         Leadiant Biosciences S.p.A.

·         Merck & Co. Inc. (Schering-Plough Corporation)

·         Pfizer Inc.

·         Shire plc (Baxalta)

·         UCB S.A.

The factors that drive the growth of the global PEGylated protein therapeutics market are increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipe line drugs are. However, high cost related to drug development and launch of generics during the forecast period are expected to impede the market growth. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.

Make an Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/3726

By product type, the colony stimulating factor segment accounted for nearly half share of the global occupational medicine market in 2017. Furthermore, the cancer segment is anticipated to grow at the highest rate of 7.4% during the forecast period.

Key Findings of the PEGylated Protein Therapeutics Market:

• North America occupied nearly two-thirds share of the global PEGylated protein therapeutics market in 2017
• The cancer segment is anticipated to grow with the highest CAGR throughout the forecast period.
• Europe is anticipated to occupy one-fifth market share of the global PEGylated protein therapeutics market by 2025.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2017, owing to FDA approval and launch of new drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR of 7.4% from 2018 to 2025, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward chronic disorders.

Access Full Summery @ https://www.alliedmarketresearch.com/PEGylated-proteins-market